| Docetaxel with estramustine (n = 33) | Docetaxel without estramustine (n = 28) | p value* |
---|---|---|---|
Age (years), median (range) | 67 (55-88) | 72 (50-82) | 0.062 |
PSA at PCa diagnosis (ng/ml), median(range) | 124.1 (10.3-4116.0) | 102.1 (4.7-19523.1) | 0.452 |
PSA at baseline (ng/ml), median(range) | 17.1 (0.6-1053.0) | 11.4 (0.8-618.4) | 0.633 |
Time from diagnosis to this chemothrapy (months), median(range) | 34 (4-176) | 37 (7-113) | 0.492 |
ECOG performance status, n (%) | Â | Â | 0.299 |
   0 | 19 (58) | 12 (43) |  |
   1 | 9 (27) | 13 (46) |  |
   2 | 5 (15) | 3 (11) |  |
Gleason score, n (%) | Â | Â | 0.517 |
   < 6 | 2 (6) | 2 (7) |  |
   7 | 9 (27) | 4 (14) |  |
   > 8 | 20 (61) | 19 (68) |  |
   unknown | 2 (6) | 3 (11) |  |
Metastatic site, n (%) | Â | Â | Â |
   Bone | 17 (52) | 16 (57) | 0.797 |
   Lymph nodes | 10 (30) | 11 (39) | 0.590 |
   Liver | 0 (0) | 1 (4) | 0.459 |
   Lung | 3 (9) | 0 (0) | 0.243 |
   None | 12 (36) | 7 (25) | 0.080 |
Prior treatment, n (%) | Â | Â | Â |
   MAB | 33 (100) | 28 (100) | ne |
   Estramustine | 33 (100) | 28 (100) | ne |
   Radical Prostatectomy | 2 (6) | 1 (4) | 1.000 |
   Radiation Therapy | 4 (12) | 3 (11) | 1.000 |
   Dexamethasone | 8 (24) | 11 (39) | 0.270 |
   Other Chemotherapy | 6 (18) | 8 (29) | 0.375 |
No. of cycles, median (range) | 5 (2-32) | 4 (2-27) | 0.382 |